| Product Code: ETC8330010 | Publication Date: Sep 2024 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Overview |
3.1 Monaco Country Macro Economic Indicators |
3.2 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, 2021 & 2031F |
3.3 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market - Industry Life Cycle |
3.4 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market - Porter's Five Forces |
3.5 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume Share, By Drugs Type, 2021 & 2031F |
3.6 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume Share, By Indication Type, 2021 & 2031F |
3.7 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.8 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing incidences of cancer, particularly breast and ovarian cancer, which are major indications for PARP inhibitors |
4.2.2 Growing demand for personalized medicine and targeted therapies in oncology |
4.2.3 Advancements in PARP inhibitor drug development and research leading to new and improved therapies |
4.3 Market Restraints |
4.3.1 High costs associated with PARP inhibitor drugs leading to limited affordability for some patients |
4.3.2 Stringent regulatory requirements for drug approval and market entry |
4.3.3 Potential side effects and safety concerns associated with long-term use of PARP inhibitors |
5 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Trends |
6 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By Types |
6.1 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By Drugs Type |
6.1.1 Overview and Analysis |
6.1.2 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Drugs Type, 2021- 2031F |
6.1.3 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Talazoparib, 2021- 2031F |
6.1.4 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Veliparib, 2021- 2031F |
6.1.5 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Olaparib, 2021- 2031F |
6.1.6 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By Indication Type |
6.2.1 Overview and Analysis |
6.2.2 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Ovarian Cancer, 2021- 2031F |
6.2.3 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Fallopian Tube Cancer, 2021- 2031F |
6.2.4 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Breast Cancer, 2021- 2031F |
6.2.5 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By End User |
6.3.1 Overview and Analysis |
6.3.2 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Homecare, 2021- 2031F |
6.3.4 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.3.5 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.4.3 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.4.4 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.4.5 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
7 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Import-Export Trade Statistics |
7.1 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Export to Major Countries |
7.2 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Imports from Major Countries |
8 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Key Performance Indicators |
8.1 Clinical trial success rates for new PARP inhibitors |
8.2 Adoption rate of PARP inhibitors in oncology treatment protocols |
8.3 Number of research publications and patents related to PARP inhibitors |
9 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market - Opportunity Assessment |
9.1 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Opportunity Assessment, By Drugs Type, 2021 & 2031F |
9.2 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Opportunity Assessment, By Indication Type, 2021 & 2031F |
9.3 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Opportunity Assessment, By End User, 2021 & 2031F |
9.4 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market - Competitive Landscape |
10.1 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenue Share, By Companies, 2024 |
10.2 Monaco Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |